Header Logo

Connection

Jeffrey Kordower to Rats

Back to Details
This is a "connection" page, showing publications Jeffrey Kordower has written about Rats.
Jeffrey Kordower
Connection Strength
2.187
Rats
  1. Enhanced CNS transduction from AAV.PHP.eB infusion into the cisterna magna of older adult rats compared to AAV9. Gene Ther. 2022 06; 29(6):390-397.
    View in: PubMed
    Score: 0.162
  2. Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. Neurobiol Dis. 2021 01; 148:105184.
    View in: PubMed
    Score: 0.158
  3. Mitomycin-C treatment during differentiation of induced pluripotent stem cell-derived dopamine neurons reduces proliferation without compromising survival or function in?vivo. Stem Cells Transl Med. 2021 02; 10(2):278-290.
    View in: PubMed
    Score: 0.156
  4. Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. Neurobiol Dis. 2018 04; 112:106-118.
    View in: PubMed
    Score: 0.130
  5. Disease Modification Through Trophic Factor Delivery. Methods Mol Biol. 2018; 1780:525-547.
    View in: PubMed
    Score: 0.129
  6. Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes In?Vivo. Stem Cell Reports. 2017 07 11; 9(1):149-161.
    View in: PubMed
    Score: 0.124
  7. Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson's Disease. J Parkinsons Dis. 2016; 6(1):77-97.
    View in: PubMed
    Score: 0.113
  8. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain. 2012 Jul; 135(Pt 7):2058-73.
    View in: PubMed
    Score: 0.088
  9. Transfer of host-derived a synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis. 2011 Sep; 43(3):552-7.
    View in: PubMed
    Score: 0.082
  10. a-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. Neurobiol Dis. 2011 Jan; 41(1):71-82.
    View in: PubMed
    Score: 0.078
  11. Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease. Neurotox Res. 2010 Jan; 17(1):66-74.
    View in: PubMed
    Score: 0.072
  12. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009 Sep; 35(3):385-98.
    View in: PubMed
    Score: 0.071
  13. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiol Dis. 2007 May; 26(2):375-84.
    View in: PubMed
    Score: 0.061
  14. Animal models of Huntington's disease. ILAR J. 2007; 48(4):356-73.
    View in: PubMed
    Score: 0.060
  15. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol. 2006 Aug; 60(2):264-8.
    View in: PubMed
    Score: 0.059
  16. Extensive neuroprotection by choroid plexus transplants in excitotoxin lesioned monkeys. Neurobiol Dis. 2006 Aug; 23(2):471-80.
    View in: PubMed
    Score: 0.058
  17. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9345-50.
    View in: PubMed
    Score: 0.058
  18. Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease. Neurology. 2006 May 23; 66(10 Suppl 4):S89-103.
    View in: PubMed
    Score: 0.058
  19. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J Comp Neurol. 2004 Jul 19; 475(2):211-9.
    View in: PubMed
    Score: 0.051
  20. Nigral-specific increase in ser31 phosphorylation compensates for tyrosine hydroxylase protein and nigrostriatal neuron loss: Implications for delaying parkinsonian signs. Exp Neurol. 2023 10; 368:114509.
    View in: PubMed
    Score: 0.048
  21. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol. 2003 Jun; 181(2):213-23.
    View in: PubMed
    Score: 0.047
  22. Excitotoxic and metabolic damage to the rodent striatum: role of the P75 neurotrophin receptor and glial progenitors. J Comp Neurol. 2002 Mar 18; 444(4):291-305.
    View in: PubMed
    Score: 0.043
  23. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease. J Neurosci. 2020 04 29; 40(18):3675-3691.
    View in: PubMed
    Score: 0.038
  24. Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models. J Clin Invest. 2020 02 03; 130(2):904-920.
    View in: PubMed
    Score: 0.037
  25. Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Sci Rep. 2013; 3:2157.
    View in: PubMed
    Score: 0.023
  26. Enduring cortical alterations after a single in-vivo treatment of HIV-1 Tat. Neuroreport. 2012 Oct 03; 23(14):825-9.
    View in: PubMed
    Score: 0.022
  27. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 2011 Nov 06; 480(7378):547-51.
    View in: PubMed
    Score: 0.021
  28. Prenatal exposure to MDMA alters noradrenergic neurodevelopment in the rat. Neurotoxicol Teratol. 2012 Jan-Feb; 34(1):206-13.
    View in: PubMed
    Score: 0.021
  29. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis. 2011 Oct; 44(1):38-52.
    View in: PubMed
    Score: 0.021
  30. Deep brain stimulation for treatment of obesity in rats. J Neurosurg. 2007 Oct; 107(4):809-13.
    View in: PubMed
    Score: 0.016
  31. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis. 2007 Jul; 27(1):67-76.
    View in: PubMed
    Score: 0.015
  32. Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Res. 2007 May 25; 1147:77-88.
    View in: PubMed
    Score: 0.015
  33. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol. 2006 Aug; 60(2):260-4.
    View in: PubMed
    Score: 0.015
  34. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis. 2006 Jan; 21(1):165-80.
    View in: PubMed
    Score: 0.014
  35. Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. Neurotoxicol Teratol. 2003 Sep-Oct; 25(5):509-17.
    View in: PubMed
    Score: 0.012
  36. Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration. J Pharmacol Exp Ther. 2003 Jul; 306(1):218-28.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.